Sowton, E., Das Gupta, D. S., and Baker, I. (1975) . Thorax, 30, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Comparative effects of beta adrenergic blocking drugs. Although many different beta blockers are now in clinical use, there is very little information concerning their relative efficacy, and it is still not clear what clinical importance should be attached to properties such as positive inotropic stimulation (intrinsic sympathomimetic activity or ISA) and membrane stabilizing action ('local anaesthetic effect' or 'quinidine-like effect'). In this report we compare the ability of patients with angina to exercise on a bicycle ergometer while receiving a series of commonly used beta blockers, and attempt to determine the importance of ISA. The investigation is in four parts with the drugs given orally or intravenously: statistical analysis of the results was carried out using standard methods, both parametric and non-parametric (Friedmann analysis of variance, Wilcoxon matched pairs signed ranks test) by two independent statisticians.
The relevant properties of drugs included in this paper are summarized in Table I . Laboratory reports using many different animal preparations may differ from this assessment under specific conditions, and the Table is intended only as a guide to the generally accepted properties of these drugs when used clinically. Results for sotalol are included for reference in the first part of this paper but the drug was withdrawn from clinical use and was not studied further. steady-state erect exercise at 300 kpm/minute on a bicycle ergometer. Control measurements were made 6 minutes after the start of the exercise, and drug-induced changes were measured a further 6 minutes following intravenous injection of one of five beta-blocking drugs. The haemodynamic results are shown in Fig. 1 , illustrating that there are considerable differences between these drugs, particularly with regard to practolol; it might be anticipated that these differences are reflected in the clinical responses of patients with angina.
been combined. The results are summarized in Table II . There is a tendency for these drugs to approach more closely the effect of propranolol as the exercise level was increased, and also (with the exception of sotalol) as the dose level was increased. , The molecular weights of the drugs are similar, and so this milligram for milligram comparison approximates to a molecule for molecule basis. The relative potencies of the drugs differ considerably and it is noteworthy that they differ -from values established in antagonism of an isoprenaline-induced tachycardia in laboratory animals (cats) as determined by Barrett and -Carter (1970) and shown in Table III exercise level on placebo tests. Also, there were no significant differences in mean age nor in the total amount of exercise performed after either placebo or active drugs. Preliminary results with two drugs have been presented elsewhere (Sowton, 1970) . Each subject underwent an exercise test, in which the maximal work load was established, and on each of four subsequent days re-exercised at levels of one quarter, one half, three quarters, and maximum tolerance. A warm-up period of exercise, followed by 20 minutes' rest, preceded the definitive test on each occasion. At rest and for two minutes at each exercise level the heart rate was measured following intravenous injection of placebo (saline) and 0 5 mg, 15 mg and 5 mg of active drug. Each investigation therefore consisted of five exercise tests, during the last three of which the subject had cumulative doses of 0 5 mg, 1X5 mg, and 5 mg of the test drug. Fig. 2 shows representative results following saline, propranolol, practolol, and alprenolol injections. The reduction in heart rate with propranolol was taken as 100% and the changes following other drugs were expressed proportionately. There were only minor differences in results for normal subjects or patients, and so these groups have (Balcon, Maloy, and Sowton, 1968) . The only other drug used was sublingual nitroglycerine, which was not taken on the morning of the investigations. Exercise testing was carried out according to a standardized protocol at 9 am on separate days in the sitting position on a bicycle ergometer (Elema-Schonander). An initial warm-up for 3 minutes at 200 kpm/minute was followed by rest until the heart rate had returned to control values (typically 20 to 30 minutes). An intravenous injection of 20 ml normal saline was given and exercise was begun 3 minutes later at a work load of 200 kpm/minute. The work load was increased by 200 kpm/minute every 3 minutes until anginal pain was produced; ECGs were continuously monitored. Recordings were taken for 15 seconds before the one-minute point and threeminute point at each work load, as well as at the onset of anginal pain. The patients were then allowed to rest again until heart rates had returned to baseline values, and 20 ml of beta-blocking solution was injected. The exercise test was then repeated using the same protocol. Assessment of exercise tolerance was made by calculating the total work performed before the onset of angina, and the improvement over saline values was taken as a measure of the drug effect. There were no complications during this investigation and no patient complained of side effects. RESULTS The mean increase in total work before pain was greatest with practolol (1,250 kpm) followed by alprenolol (1,050 kpm) and oxprenolol (575 kpm) with propranolol, the only drug 
group.bmj.com on July 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from without ISA, the lowest (340 kpm). However, the difference between propranolol and practolol results has a P value of only 0-10. Table IV shows increase in work for each drug, together with a ranking order in which 1 represents the best drug and 4 the worst. A non-parametric analysis of variance shows that alprenolol and practolol are indistinguishable and that both are better than propranolol (P<0 10) with oxprenolol intermediate and not significantly different.
It is possible that a training effect occurred during the trial. If the mean values for increase in work on each day are taken irrespective of the drug given, the values in Table V are obtained. Values for the first day are significantly (P<0'05) lower than those for the second day, both for saline and for active drug. There is no significant difference between the second and third days, nor between the third and fourth. It is impossible for all combinations of order of administration to be achieved with the number of patients available, and the randomization resulted in seven of the 12 propranolol tests occurring on the fourth day. It is possible that this unfavourably influenced the propranolol results, but even when this factor is considered, together with the likelihood that the doses chosen were not equivalent for all patients, the differences we found were only at the 10% level.
COMPARATIVE ORAL TRIAL IN ANGINA
The purpose of this portion of the investigation was to determine whether the differing haemodynamic properties discussed earlier, in particular the presence of ISA, had clinical importance in the treatment of angina, and also to assess if the responses to intravenous doses correlated with those following oral administration. A doubleblind crossover trial was carried out in 20 patients with typical histories of angina who were already stabilized on propranolol as a clinical treatment. In view of reports that replacement of oxprenolol, practolol or propranolol with placebo may result in a severe exacerbation of angina (Turner and Peel, 1970) , we felt it unethical to include a placebo in this particular group and so the trial was carried out using five beta blockers only. Criteria for exclusion were similar to those for the intravenous trial, with the addition of gastrointestinal disturbances; seven of the patients completing the intravenous trial also took part in the oral trial and their results are compared later as a separate group.
After a run-in period on beta blockers of at least six weeks, including an exercise test as previously described, the patients had another standard exercise test at entry to the trial proper. Clinical examination, 12-lead ECG, laboratory tests for serum enzymes, blood urea, haemoglobin, blood film ESR, and electrolytes, together with further exercise tests including a warm-up, were then carried out every two weeks over a 10-week period. At each visit patients were questioned about side effects, and a nitroglycerine test, as described by Fitzgerald (1970) , was carried out to confirm beta blockade.
The drugs used, and the 'equivalent doses' chosen after consultation with the manufacturers, are shown in Table VI . Nitroglycerine test This test was carried out at each visit, as described by Fitzgerald (1970) 
DISCUSSION
The haemodynamic changes produced by beta blockers we report here are in keeping with many other reports in the literature which, however, usually deal with individual drugs. Despite these differences all the drugs resulted in very similar exercise performance after either intravenous or oral administration. Administration of drugs with ISA was associated with higher resting heart rates than during propranolol therapy in each of our studies reported here, and this is in keeping with published findings (Hill and Turner, 1969; Hetherington, Comerford, Nyberg, and Besterman, 1973; Gibson, 1974) . In our oral five drug trial, the highest resting rates were found with pindolol, which has the greatest ISA, and the lowest with propranolol, as expected, but the differences were not great and do not reach the 5% level. During exercise, differences between the drugs were even less apparent and the increase in exercise tolerance following intravenous injection could not be related to ISA, cardioselectivity or presence of membrane-stabilizing effect. After oral administration also, the exercise tolerance did not differ according to the non-adrenergic blocking properties of the drugs. Similar conclusions concerning practolol and propranolol were reported by Coltart (1971) and concerning practolol and alprenolol by Sowton (1970) . In both these reports individual patients who failed to respond to one drug had very similar exercise performance on the second drug. A similar response occurred in the intravenous trial reported here (patient 5, Table IV ). The importance of properties apart from adrenergic receptor blockade in determining the depression of cardiac function produced by different drugs has been widely discussed, and it is often held that drugs with ISA cause less depression and so are clinically preferable (Grandjean and Rivier, 1968; Turner and Peel, 1970 ).
This view is not supported by Gibson (1974) who has extensively reviewed published data and shown that reductions in cardiac output, blood pressure, and heart rate are linearly related for all beta blockers except practolol, and that results with all non-cardioselective drugs so far published can be expressed by a single regression line. Hetherington et al. (1973) found no difference in cardiac depression between oral alprenolol and propranolol in patients with angina; a similar conclusion was reached by Kerber, Goldman. Alderman, and Harrison (1972) .
The importance of adjusting the dose of beta blockers for an individual patient has been emphasized, particularly by Gillam and Prichard (1966) for propranolol, and by Sealey, Liljedal, Nyberg, and Ablad (1971) for alprenolol, as well as by many other workers, and our oral comparison trial goes some way towards this. In any crossover double-blind trial it is not possible to adjust doses of the separate drugs independently, and so it is unlikely that our patients were taking optimal doses during each treatment period. Another complicating factor may be that different patients were not at similar points on the dose-response curve with the same drug, while the situation may be different again with different drugs, even if the dose-response curves are parallel and the same for different patients. Despite these theoretical difficulties in comparing drugs our patients were taking doses which produced very similar clinical effects in reduction of exercise, tachycardia, and improvement of exercise capacity. In particular, the presence of differing degrees of ISA did not affect the exercise results. This is in keeping with an acute trial reported by Thudani et al. (1973) , who found that practolol, oxprenolol, and propranolol given in doses which produced similar reductions in exercise heart rate all had similar anti-anginal effects. Similarly, our present results agree with those of Gibson (1974) , who reported no difference between intravenous oxprenolol, practolol, and alprenolol compared with propranolol when judged by the reduction of heart rate from any given resting rate. Our findings also agree with those of Coltart (1972) , who was unable to show any significant difference in exercise tolerance of patients with angina during treatment with propranolol, practolol or oxprenolol, given intravenously, orally for three days, or after long-term oral therapy on optimal doses. Agreement between intravenous and oral responses following alprenolol has also been reported (Sealey et al., 1971) . It is reasonable to conclude from these intravenous trials that ISA is of little importance, but during oral administration the situation is different. Propranolol given orally is metabolized in part to 4-hydroxy propranolol in the liver, and this substance is itself a beta adrenergic blocker which possesses ISA (Fitzgerald and O'Donnell, 1971 ). This theoretical difference was not reflected in our results, and others (Turner and Peel, 1970) have reported similar findings from intravenous and oral propranolol. It is difficult to reconcile these authors' findings that oxprenolol and pindolol behave differently when given intraveously or orally with our own results; their own explanation that the difference from propranolol is due to the lack of ISA possessed by propranolol is untenable when account is taken of the ISA possessed by the 4-hydroxy metabolite.
The report by Wilson et al. (1968) that the drop in cardiac output produced by intravenous oxprenolol was not found after one month's oral administration could not be confirmed by Majid et al. (1970) ; from the same group a similar claim for pindolol (Turner and Peel, 1970 ) also remains unconfirmed.
The similarity of heart rate responses and exercise ability produced by the different drugs in our seven patients studied with both intravenous and oral administration (Tables XI and XII) leads us to conclude that ISA possessed by the original drug or by its metabolites has negligible importance clinically. A similar conclusion was reached by Taylor, Thudani, and Sharma (1972) .
Our results with pindolol are surprising since the patients performed significantly less work on this drug than on the other four (Tables VII and  VIII) despite apparently equivalent beta blockade, as shown by virtually identical heart rates after equivalent exercise (Table VII , column 6), by similar results to the nitroglycerine test (Table  VIII) , and by the satisfactory blood levels of pindolol ( Table X ). The differences cannot be due to patient selection since all drugs were tested in the same patients. The possibility that exercising blood pressures were consistently higher on pindolol than on any of the other beta blockers is extremely unlikely in view of the known hypotensive actions of pindolol (Doyle et al., 1972; Duner, 1972) and the drop in systemic pressure on exercise shown by McCredie (1970) . It also seems unlikely that the dose we used was too small since the maximum heart rates achieved on exercise were slower with pindolol than with any other drug. It is possible that the dose was in fact too large, and the manufacturers have some evidence to suggest t1hat the beneficial effect in angina is reduced at doses above 30 mg per day (Maclay, 1974, personal communication) . Nine of our 17 patients were taking 30 mg or more of pindolol daily. We have previously reported a reduction of anti-anginal effect when the dose was increased in a group of patients taking alprenolol (Sowton and Smithen, 1971) ; it is possible that exercise was limited by peripheral effects, but elucidation of this finding requires further work.
Scrutiny of our individual results suggests that some patients consistently performed better on one of the oral preparations, although this effect was not confined to any one of the drugs. It is possible that this represents incorrect comparative dosage for particular patients. If the data we obtained during intravenous administration applies also to the oral route, comparative doses might vary from patient to patient according to the relative levels of exercise achieved, and might also vary in a single patient from time to time.
The data with oral administration of alprenolol and propranolol reported by Hetherington et al. (1973) are very similar to our intravenous findings, suggesting a similar pattern of change in comparative doses.
An alternative explanation, which we consider less likely, is that some patients respond better to a specific drug; this point cannot be decided without individual dose-response curves, which are beyond the scope of the present investigation. It is well recognized that exercise tolerance in patients with angina can vary from day to day; this factor doubtless played a part in our findings and may even be sufficient to explain chance improvements with particular drugs on several occasions.
The clinical implication is that a patient whose angina fails to respond to a beta blocker should initially be treated with an increased dose, but that a different drug should be substituted if there is still no increase in exercise capacity. Our interpretation of these results is that improvement on a second or third beta blocker is unlikely when the first drug has failed. We see no indication to change beta blockers when a patient has responded well to the initial drug, except possibly when side effects such as asthma or gastrointestinal disturbances are troublesome. As our results indicate little clinical difference between the drugs at these doses, the therapeutic choice can be made on the basis of side effects for individual patients.
CONCLUSIONS
In our patients we have shown: 1. good correlation between the effects of intravenous and oral administration of these beta blocking drugs in patients with angina pectoris; 2. that the possession of intrinsic sympathomimetic activity was of no clinical importance; 3. that haemodynamic differences on mild exercise between different beta blocking drugs were not reflected in ability to improve exercise performance; and 4. that at the doses we used, there was no significant difference on exercise testing between propranolol, practolol, oxprenolol, itnd alprenolol given to angina patients intravenously or orally.
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